Seelos Therapeutics, Inc.: accounts_receivable
| Value | {"amount": 652000, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} |
|---|---|
| Period | (as of 2012-12-31) |
| Status | current |
| Entity | Seelos Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T09:53:11.864121+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/e3674db1-8754-412d-bc4d-b219df20245f
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001017491-14-000052 · Open the official SEC filing →Retrieved: 2026-08-19T09:53:11.864121+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001017491/accounts-receivable/2012-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/e3674db1-8754-412d-bc4d-b219df20245f
History
- supersedes {"amount": 653000, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} (evidence 0001193125-13-334791)